Purpose
To determine the lipoprotein distribution of Torcetrapib in normolipidemic or hyperlipidemic human plasma and assess any changes in distribution due to lipid profile.
Methods
Torcetrapib was incubated with human plasma samples, and the distribution was measured across four fractions: triglyceride-rich lipoprotein (TRL), low-density lipoprotein, high-density lipoprotein, and lipoprotein-deficient plasma fraction. Two stocks of human plasma were used, one considered normolipidemic (total cholesterol concentration = 164 mg/dL, triglycerides concentration = 139 mg/dL, protein concentration = 912 mg/dL), the other hyperlipidemic (total cholesterol = 260 mg/dL, triglycerides = 775 mg/dL, protein = 917 mg/dL). The plasma samples were incubated with Torcetrapib at 37°C, and the incubation was stopped with the addition of sodium bromide and cooling to 4°C. The plasma samples were then separated by density gradient ultracentrifugation to their lipoprotein fractions. The resulting lipoprotein fractions and an aliquot of incubated plasma were analyzed by a validated gas chromatography/tandem mass spectrometry analytical method. The distribution of Torcetrapib was determined first with varying incubation times, then with several concentrations.
Results
At concentrations of 250 and 500 ng/mL, Torcetrapib distributed evenly across the four fractions in normolipidemic plasma. At the same concentrations in hyperlipidemic plasma, approximately 84% of Torcetrapib was found in the TRL fraction, with the remaining 16% evenly partitioned between the low-density lipoprotein, high-density lipoprotein, and lipoprotein-deficient plasma fractions.
Conclusions
The results suggest that lipid profile affects the distribution of Torcetrapib in hyperlipidemic human plasma lipoprotein fractions. The preferential distribution of Torcetrapib into the TRL fraction in hyperlipidemic plasma needs to be investigated to see if it will affect the pharmacological effect of Torcetrapib in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
K. M. Wasan S. M. Cassidy (1998) ArticleTitleModifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs J. Pharm. Sci. 87 411–424 Occurrence Handle9548892 Occurrence Handle1:CAS:528:DyaK1cXhs1ChsLw%3D Occurrence Handle10.1021/js970407a
C. B. Hesler A. R. Tall T. L. Swenson P. K. Weech Y. L. Marcel R. W. Milne (1988) ArticleTitleMonoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma J. Biol. Chem. 263 IssueID11 5020–5023 Occurrence Handle3281933 Occurrence Handle1:CAS:528:DyaL1cXitVagsb0%3D
A. R. Tall (1993) ArticleTitlePlasma cholesteryl ester transfer protein J. Lipid Res. 34 1255–1274 Occurrence Handle8409761 Occurrence Handle1:CAS:528:DyaK3sXmt1agtr4%3D
Y. C. Ha P. J. Barter (1982) ArticleTitleDifferences in plasma cholesteryl ester transfer activity in sixteen vertebrate species Comp. Biochem. Physiol. B. 71 IssueID2 265–269 Occurrence Handle7060347 Occurrence Handle1:STN:280:DyaL387jslyjsw%3D%3D Occurrence Handle10.1016/0305-0491(82)90252-8
P. Moulin (1996) ArticleTitleCholesteryl ester transfer protein: an enigmatic protein Horm. Res. 45 IssueID3–5 238–244 Occurrence Handle8964591 Occurrence Handle1:CAS:528:DyaK28XhvFKmsrw%3D Occurrence Handle10.1159/000184795
A. R. Tall E. Abreu J. Shuman (1983) ArticleTitleSeparation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein J. Biol. Chem. 258 IssueID4 2174–2180 Occurrence Handle6822552 Occurrence Handle1:CAS:528:DyaL3sXht1Wls78%3D
R. E. Morton D. B. Zilversmit (1982) ArticleTitlePurification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma J. Lipid Res. 23 IssueID7 1058–1067 Occurrence Handle7142814 Occurrence Handle1:CAS:528:DyaL3sXmslChsQ%3D%3D
A. R. Tall (1995) ArticleTitlePlasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies J. Intern. Med. 7 IssueID1 5–12 Occurrence Handle10.1111/j.1365-2796.1995.tb01133.x
P. J. Barter B. B. Brewer M. J. Chapman C. H. Hennekens D. J. Rader A. R. Tall (2003) ArticleTitleCholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler. Thromb. Vasc. BioI. 23 IssueID2 160–167 Occurrence Handle1:CAS:528:DC%2BD3sXptF2jsw%3D%3D Occurrence Handle10.1161/01.ATV.0000054658.91146.64
M. E. Brousseau M. R. Diffenderfer J. S. Millar C. Nartsupha B. F. Asztalos F. K. Welty M. L. Wolfe M. Rudling I. Bjorkhem B. Angelin J. P. Mancuso A. G. Digenio D. J. Rader E. J. Schaefer (2005) ArticleTitleEffects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism and fecal sterol excretion Arterioscler. Thromb. Vasc. Biol. 25 IssueID5 1057–1064 Occurrence Handle15761191 Occurrence Handle1:CAS:528:DC%2BD2MXjsVCjtLc%3D Occurrence Handle10.1161/01.ATV.0000161928.16334.dd
M. E. Brousseau, E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. Effects of an inhibitor of cholesteryl ester transfer protein on HDL Cholesterol. N. Engl. J. Med. 350(15):1505–1515.
K. Maeda H. Okamoto H. Shinkai (2004) ArticleTitle S-(2-(Acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors Bioorg. Med. Chem. Lett. 14 IssueID10 2589–2591 Occurrence Handle15109658 Occurrence Handle1:CAS:528:DC%2BD2cXjsVKhtLY%3D Occurrence Handle10.1016/j.bmcl.2004.02.071
R. W. Clark T. A. Sutfin R. B. Ruggeri A. T. Willauer E. D. Sugarman G. Magnus-Aryitey P. G. Cosgrove T. M. Sand R. T. Wester J. A. Williams M. E. Perlman M. J. Bamberger (2004) ArticleTitleRaising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of Torcetrapib Arterioscler. Thromb. Vasc. Biol. 24 IssueID3 490–497 Occurrence Handle14739125 Occurrence Handle1:CAS:528:DC%2BD2cXhvFOis7c%3D Occurrence Handle10.1161/01.ATV.0000118278.21719.17
D. B. Lloyd M. E. Lira L. S. Wood L. K. Durham T. B. Freeman G. M. Preston X. Qiu E. Sugarman P. Bonnette A. Lanzetti P. M. Milos J. F. Thompson (2005) ArticleTitleCholesteryl ester transfer protein variants have differential stability but uniform inhibition by Torcetrapib J. Biol. Chem. 280 IssueID15 14918–14922 Occurrence Handle15681846 Occurrence Handle1:CAS:528:DC%2BD2MXjtFSls7g%3D Occurrence Handle10.1074/jbc.M500523200
H. Okamoto F. Yonemori K. Wakitani T. Minow K. Maeda H. Shinkai (2000) ArticleTitleA cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 IssueID6792 203–207 Occurrence Handle10910363 Occurrence Handle1:CAS:528:DC%2BD3cXlsVWgtrY%3D Occurrence Handle10.1038/35018119
H. V. Kothari K. J. Poirier W. H. Lee Y. Satoh (1997) ArticleTitleInhibition of cholesteryl ester transfer protein by GGS 25159 and changes in lipoproteins in hamsters Atherosclerosis 128 IssueID1 59–66 Occurrence Handle9051198 Occurrence Handle1:CAS:528:DyaK28Xnt1Klsbk%3D Occurrence Handle10.1016/S0021-9150(96)05981-3
G. J. Grooth Particlede J. A. Kuivenhoven A. F. H. Stalenhoef J. Graaf Particlede A. H. Zinderman J. L. Posma A. Tol Particlevan J. J. P. Kastelein (2002) ArticleTitleEfficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response study Circulation 105 IssueID18 2159–2165 Occurrence Handle11994249 Occurrence Handle10.1161/01.CIR.0000015857.31889.7B Occurrence Handle1:CAS:528:DC%2BD38XktlOku70%3D
K. M. Wasan P. H. Pritchard M. Ramaswamy W. Wong E. M. Donnachie L. J. Brunner (1997) ArticleTitleDifferences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine Pharm. Res. 14 IssueID11 1613–1620 Occurrence Handle9434283 Occurrence Handle1:CAS:528:DyaK2sXotVGmsrg%3D Occurrence Handle10.1023/A:1012190620854
D. P. Rossignol K. M. Wasan E. Choo E. Yau N. Wong J. Rose J. Moran M. Lynn (2004) Antimicrob. Agents Chemother. 48 IssueID9 3233–3240 Occurrence Handle15328078 Occurrence Handle1:CAS:528:DC%2BD2cXnsVeiuro%3D Occurrence Handle10.1128/AAC.48.9.3233-3240.2004
R. M. Procyshyn N. B. Kennedy S. Marriage K. M. Wasan (2001) ArticleTitlePlasma protein and lipoprotein distribution of clozapine Am. J. Psychiatry 158 IssueID6 949–951 Occurrence Handle11384905 Occurrence Handle1:STN:280:DC%2BD3MzhtFCntQ%3D%3D Occurrence Handle10.1176/appi.ajp.158.6.949
N. S. Chung K. M. Wasan (2004) ArticleTitlePotential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake Adv. Drug Deliv. Rev. 56 IssueID9 1315–1334 Occurrence Handle15109771 Occurrence Handle1:CAS:528:DC%2BD2cXjtl2ktrc%3D Occurrence Handle10.1016/j.addr.2003.12.003
Acknowledgment
Funding for this project was provided by Pfizer, Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, S.D., Wasan, K.M., Calcagni, A. et al. The in Vitro Plasma Distribution of a Novel Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, Is Influenced by Differences in Plasma Lipid Concentrations. Pharm Res 23, 1025–1030 (2006). https://doi.org/10.1007/s11095-006-9908-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-006-9908-2